12:00 AM
 | 
Apr 28, 2014
 |  BC Week In Review  |  Company News  |  Deals

Epizyme, GlaxoSmithKline deal

Epizyme will receive a $4 million milestone payment from GlaxoSmithKline under a 2011 deal in which the companies partnered to discover, develop and commercialize small molecule therapeutics targeting histone methyltransferases for cancer...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >